Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Jennifer A WoyachAmy S RuppertNyla A HeeremaWeiqiang ZhaoAllison M BoothWei DingNancy L BartlettDanielle M BranderPaul M BarrKerry A RogersSameer A ParikhSteven CoutreArti HurriaJennifer R BrownGerard LozanskiJames S BlachlyHatice G OzerBrittny Major-ElechiBriant FruthSreenivasa NattamRichard A LarsonHarry ErbaMark LitzowCarolyn OwenCharles KuzmaJeremy S AbramsonRichard F LittleScott E SmithRichard M StoneSumithra J MandrekarJohn C ByrdPublished in: The New England journal of medicine (2018)
Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression-free survival. There was no significant difference between ibrutinib and ibrutinib plus rituximab with regard to progression-free survival. (Funded by the National Cancer Institute and Pharmacyclics; ClinicalTrials.gov number, NCT01886872 .).